Debate on the treatment of multiple sclerosis: Experience from an intractable multiple sclerosis case with rebound syndrome after fingolimod cessation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Debate on the treatment of multiple sclerosis: Experience from an intractable multiple sclerosis case with rebound syndrome after fingolimod cessation

Published:2019-03 Issue:S1 Volume:10 Page:59-62
ISSN:1759-1961
Container-title:Clinical and Experimental Neuroimmunology
language:en
Short-container-title:Clin Exp Neuroimmunol

Author:

Kuroda Hiroshi¹,Nishiyama Shuhei¹,Matsumoto Yuki¹,Misu Tatsuro¹²,Fujihara Kazuo¹²³,Aoki Masashi¹

Affiliation:

1. Department of Neurology Tohoku University Graduate School of Medicine Sendai Japan

2. Department of Multiple Sclerosis Therapeutics Tohoku University Graduate School of Medicine Sendai Japan

3. Department of Multiple Sclerosis Therapeutics Fukushima Medical University School of Medicine Fukushima Japan

Publisher

Wiley

Subject

Neurology (clinical),Immunology and Microbiology (miscellaneous),Immunology,Neuroscience (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cen3.12504

Reference20 articles.

1. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

2. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

3. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment

4. Rebound of Disease Activity After Withdrawal of Fingolimod (FTY720) Treatment

5. Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fingolimod withdrawal;Reactions Weekly;2019-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP